SAT-LB097 The Effect of (131)I Treatment on Pregnancy Outcomes after Thyroidectomy in Patients with Differentiated Thyroid Carcinoma: A Meta-Analysis

Background and objective: Differentiated thyroid carcinoma (DTC) is the most common malignancy of the endocrine system, which is more prevalent in women and particularly during the reproductive years. Iodine-131 ((131)I) has been used to treat DTC for many years. As several studies have reported inconsistent findings on the effects of (131)I treatment on pregnancy outcomes after DTC surgery. This meta-analysis was undertaken to assess and clarity the association between (131)I treatment and pregnancy outcomes. Methods: Electronic database PubMed, Embase, The Cochrane Library were throughly search until December 2017. Meta-analysis was performed in Stata/SE12. The statistical results of the meta-analysis were shown in the forest diagram. Results: A total of 7 observational studies were eligible, involving 14212 participants and 3106 pregnancies. It showed that postoperative (131)I treatment for DTC had no significant effect on spontaneous abortion (OR = 1.05, P = 0.703);induced abortion (OR = 1.05, P = 0.861); abortion (OR = 1.08, P = 0.574);premature birth (OR = 1.50, P = 0.064); stillbirth (OR=0.63, P=0.406) ;The group in which interval time between last (131)I treatment and pregnancy >1 year had lower risk of abortion than with interval <1 year (OR = 0.52, P = 0.000), and the difference was statistically significant. (131)I dose > 3.7GBq and < 3.7GBq had no effect on abortion (OR = 0.91, P = 0.526). Conclusions: The group in which interval between last (131)I treatment and pregnancy >1 year had lower risk of abortion than that with interval <1 year . Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.